$2.29
9.57%
Nasdaq, Nov 11, 03:59 pm EST. Closed.
ISIN
US3724461047
Symbol
GNPX

Genprex, Inc. Stock price

$2.09
-0.60 22.30% 1M
-16.51 88.76% 6M
-36.41 94.57% YTD
-85.91 97.63% 1Y
-9,809.91 99.98% 3Y
-94,597.91 100.00% 5Y
-206,797.91 100.00% 10Y
-206,797.91 100.00% 20Y
Nasdaq, Closing price Tue, Nov 10 2026
+0.03 1.46%
ISIN
US3724461047
Symbol
GNPX
Industry

Is Genprex, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,093 stocks worldwide.

Key metrics

Basic
Market capitalization
$1.7m
Enterprise Value
$-13.4m
Net debt
positive
Cash
$15.2m
Shares outstanding
510.0k
Valuation
P/E
negative
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
0.9 | 0.9
P/B
0.1
Financial Health
Equity Ratio
78.4%
Return on Equity
-
ROCE
-107.1%
ROIC
-
Debt/Equity
0.0
Financials
Revenue | estimate
$0.0 | $0.0
EBITDA
-
EBIT
$-15.8m
Net Income
$-16.5m
Free Cash Flow | ex SBC
$-15.6m | $-15.4m
Growth
Revenue | estimate
- | -
EBITDA
-
EBIT
8.5%
Net Income
6.0%
Free Cash Flow
-10.5%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
$-34.9
FCF per Share
$-30.5
Short interest
15.3%
Employees
13
Rev per Employee
-

Genprex, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Genprex, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Genprex, Inc. forecast:

Buy
86%
Hold
14%

Genprex, Inc. Events

Upcoming Event
NOV
12
Q3 2026 Earnings Call
TOMORROW

Financial data from Genprex, Inc.

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 6.02 6.02
10% 10%
-
- Research and Development Expense 9.82 9.82
8% 8%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -16 -16
8% 8%
-
Net Profit -17 -17
6% 6%
-

In millions USD.

Don't miss a Thing! We will send you all news about Genprex, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Genprex, Inc. Stock News

Neutral
PRNewsWire
●
about 10 hours ago
Genprex Senior Director of Quality Control & Product Development to Present Insights from Parallel AAV and Lipid-Based Development Programs Presentation to Highlight Drug Development, Manufacturing and Optimization Considerations for Diabetes Gene Therapy AUSTIN, Texas, Nov. 11, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage biotechnology compan...
Neutral
PRNewsWire
●
6 days ago
Whole-Blood Translational Analysis from Clinical Trial Patients Link TUSC2 to Mitochondrial Adaptation, Autophagy, and Protein Quality Control Expands Upon Existing REQORSA Research, Supporting Potential Beyond Oncology AUSTIN, Texas, Nov. 5, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage biotechnology company developing gene therapies designed ...
Neutral
PRNewsWire
●
7 days ago
Research to be Presented at the 2026 EORTC-NCI-AACR Symposium Links TROP2 Expression to Treatment Response and Explores its Role in Treatment Sensitivity Findings Suggest Low TROP2 Expression is Associated with Primary Resistance to REQORSA and May Help Guide Patient Selection AUSTIN, Texas, Nov. 4, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage...
More Genprex, Inc. News

Company Profile

Genprex, Inc. is a clinical stage gene therapy company, which engages in the development of novel proprietary technology platform for the treatment of cancer. It develops the Oncoprex immunogene therapy which targets the non-small cell lung cancer and other solid tumors. The company was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.

Head office United States
CEO Mr. Confer
Employees 13
Founded 2009
Website www.genprex.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today